Allison Bratzel
Stock Analyst at Piper Sandler
(2.18)
# 1,500
Out of 4,412 analysts
23
Total ratings
41.18%
Success rate
-0.25%
Average return
Main Sectors:
Top Industries:
9 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding | Maintains: Overweight | $28 | $14.53 | +92.70% | 2 | Mar 26, 2024 | |
| HUMA Humacyte | Maintains: Neutral | $4 | $3.99 | +0.25% | 2 | Mar 26, 2024 | |
| SLDB Solid Biosciences | Upgrades: Overweight | $8 → $20 | $8.98 | +122.72% | 4 | Mar 14, 2024 | |
| ARGX argenx SE | Maintains: Overweight | $518 → $522 | $372.80 | +40.02% | 9 | Jan 26, 2024 | |
| ROIV Roivant Sciences | Initiates: Overweight | $20 | $11.03 | +81.32% | 1 | Jan 5, 2024 | |
| ABCL AbCellera Biologics | Assumes: Overweight | $20 | $3.76 | +431.91% | 1 | Oct 13, 2023 | |
| REPL Replimune Group | Assumes: Overweight | $44 | $6.42 | +585.36% | 1 | Apr 17, 2023 | |
| RIGL Rigel Pharmaceuticals | Assumes: Neutral | $2 | $1.10 | +81.82% | 1 | Apr 3, 2023 | |
| INCY Incyte | Maintains: Overweight | $100 | $51.68 | +93.50% | 2 | Feb 8, 2023 |
Scholar Rock Holding
Mar 26, 2024
Maintains: Overweight
Price Target: $28
Current: $14.53
Upside: +92.70%
Humacyte
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $3.99
Upside: +0.25%
Solid Biosciences
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $8.98
Upside: +122.72%
argenx SE
Jan 26, 2024
Maintains: Overweight
Price Target: $518 → $522
Current: $372.80
Upside: +40.02%
Roivant Sciences
Jan 5, 2024
Initiates: Overweight
Price Target: $20
Current: $11.03
Upside: +81.32%
AbCellera Biologics
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $3.76
Upside: +431.91%
Replimune Group
Apr 17, 2023
Assumes: Overweight
Price Target: $44
Current: $6.42
Upside: +585.36%
Rigel Pharmaceuticals
Apr 3, 2023
Assumes: Neutral
Price Target: $2
Current: $1.10
Upside: +81.82%
Incyte
Feb 8, 2023
Maintains: Overweight
Price Target: $100
Current: $51.68
Upside: +93.50%